var data={"title":"House dust mite sublingual tablet: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">House dust mite sublingual tablet: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/808402?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=house-dust-mite-sublingual-tablet-patient-drug-information\" class=\"drug drug_patient\">see &quot;House dust mite sublingual tablet: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49661634\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Severe allergic reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">House dust mite allergen extract can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not administer to patients with severe, unstable, or uncontrolled asthma.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Observe patients in the office for at least 30 minutes following the initial dose.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">House dust mite allergen extract may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">House dust mite allergen extract may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50280301\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Odactra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50280302\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Acarizax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49661636\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Allergen-Specific Immunotherapy</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50010713\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>House dust mite-induced allergic rhinitis:</b> Sublingual: One tablet once daily. <b>Note:</b> Data regarding restarting treatment after missing a dose are limited; in clinical trials, treatment interruptions &le;7 days were allowed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50010714\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50010715\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50870967\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Sublingual, Sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Odactra: 12 SQ-HDM</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50870966\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50280303\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, Sublingual:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acarizax: 12 SQ-House Dust Mite Allergen</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49661633\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Odactra: FDA approved March 2017; anticipated availability is currently undetermined</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50010716\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer the first dose in a healthcare setting due to the potential for allergic reactions; monitor patient for &ge;30 minutes after first dose. If well tolerated, subsequent doses may be taken at home. With dry hands, remove sublingual tablet from blister immediately prior to administration. Place tablet under tongue until completely dissolved and then wait at least 1 minute before swallowing. Wash hands after handling tablet. Avoid food or beverage for 5 minutes following administration. Auto-injectable epinephrine should be made available to patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49661638\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>House dust mite-induced allergic rhinitis:</b> Treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to <i>Dermatophagoides farinae</i> or <i>D. pteronyssinus</i> house dust mites, or skin testing to licensed house dust mite allergen extracts in adults &le;65 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated for the immediate relief of allergic symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49710911\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Oral itching (61%), swelling of lips (18%), swollen tongue (16%), glossalgia (14%), nausea (14%), tongue ulcer (12%), stomach pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Mouth edema (20%, uvula)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local pruritus (in the ear; 52%), local swelling (uvula/back of the mouth; 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Throat irritation (67%), pharyngeal edema (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest discomfort (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Mouth pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Urticaria (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (10%), oral mucosa ulcer (10%), oral paresthesia (9%), diarrhea (7%), tongue pruritus (5%), stomatitis (3%), vomiting (3%), dyspepsia (2% to 3%), gastroesophageal reflux disease (2%), oral mucosa erythema (2%), dysphagia (1%), lip pruritus (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye pruritus (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngeal erythema (2%), sneezing (2%), upper respiratory tract infection (2%), dry throat (1%), oropharyngeal pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Hypersensitivity: Anaphylaxis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49661639\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to any component of the formulation; severe, unstable, or uncontrolled asthma; history of any severe systemic allergic reaction; history of any severe local reaction after taking any sublingual allergen immunotherapy; history of eosinophilic esophagitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Coadministration with beta-blockers; active oral cavity inflammatory conditions (eg, oral lichen planus with ulcerations, severe oral candidiasis, dental extraction).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50010709\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concerns related to adverse effects:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophagitis: Eosinophilic esophagitis has been reported with sublingual tablet immunotherapy; discontinue therapy in patients who experience severe or persistent gastroesophageal symptoms (eg, dysphagia, chest pain). Use is contraindicated in patients with a history of eosinophilic esophagitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions:<b> [US Boxed Warning]: Life-threatening allergic reactions, including anaphylaxis and severe laryngopharyngeal restrictions, may occur.</b> Local reactions in the mouth or throat may occur; consider discontinuation in patients experiencing escalating and persistent adverse reactions in the mouth or throat. Increased risk of local or systemic adverse reactions may occur when given with concomitant allergen immunotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease-related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: <b>[US Boxed Warning]: Do not administer to patients with severe, unstable, or uncontrolled asthma</b>. Withhold treatment if patient is experiencing an acute asthma exacerbation. Re-evaluate patients with recurrent asthma exacerbations and consider discontinuation. Use is contraindicated in patients with unstable or uncontrolled asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: <b>[US Boxed Warning]: Auto-injectable epinephrine should be prescribed to patients; instruct patients on appropriate use and to obtain immediate medical care upon its use.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate patient selection: <b>[US Boxed Warning]: Use may not be suitable for patients with conditions that may reduce their ability to survive a serious allergic reaction</b>, including but not limited to markedly compromised lung function (chronic or acute) and cardiovascular conditions (eg, unstable angina, recent MI, significant arrhythmia, uncontrolled hypertension).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: Use may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators due to concomitant drug therapy.</b> The effect of epinephrine may be potentiated or inhibited by the following medications: Beta blockers, alpha blockers, ergot alkaloids, tricyclic antidepressants, levothyroxine, monoamine oxidase inhibitors, antihistamines (ie, chlorpheniramine, diphenhydramine), cardiac glycosides, and diuretics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced health care provider: Should be administered under the supervision of healthcare providers experienced in the diagnosis and treatment of allergic diseases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monitoring: <b>[US Boxed Warning]: Monitor all patients for at least 30 minutes after initial dose</b> in a healthcare setting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral inflammation/wounds: Discontinue therapy to allow for complete healing of the oral cavity due to oral inflammation (eg, oral lichen planus, mouth ulcers, or thrush) or oral wounds following oral surgery or dental extraction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49711511\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49711508\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=112242&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50010707\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Information related to the use of house dust mite allergen extract in pregnant women is limited (Shaikh 2012). In general, allergy immunotherapy may continue in women tolerating treatment who become pregnant after therapy has started. However, initiating allergy immunotherapy during pregnancy is generally avoided (Larenas-Linnemann 2016; Oykhman 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50010708\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50010718\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs/symptoms of hypersensitivity; monitor patients for at least 30 minutes after administration of first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50010712\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">While the exact mechanism has not been fully elucidated, specific immunotherapy (SIT) may act by inducing a switch from T helper 2 cell response (Th2) to T helper 1 cell (Th1) response resulting in decreased interleukin-4 (IL-4) and interleukin-5 (IL-5) and increased interleukin-10 (IL-10), production of IgG-blocking antibodies that compete with IgE antibodies for allergen binding, proliferation of regulatory T lymphocytes and cytokines, and decreases in mast cells, eosinophils, and early- and late-phase allergic responses (Leith 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51083809\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Odactra Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12SQ-HDM (1): $11.65</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49710651\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acarizax (AU, CZ, DK, FR, NO, PL);</li>\n      <li>Acarizax 12 SQ-HDM (AT, SK);</li>\n      <li>Acaroid (DE);</li>\n      <li>Actair (AU, JP);</li>\n      <li>Allergens from House Dust for Diagnosis (BG);</li>\n      <li>Alustal (DE, HU, LT, LU, NZ, RO);</li>\n      <li>Alustal House Dust Mite Extract (AU);</li>\n      <li>Alutard SQ (CN);</li>\n      <li>Lais (KR);</li>\n      <li>Miticure (JP);</li>\n      <li>ModALL (DE);</li>\n      <li>Staloral Mites (KW, QA, SA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acarizax (house dust mite allergen extract) [product monograph]. H&oslash;rsholm, Denmark: ALK-Abello; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update [published correction appears in <i>J Allergy Clin Immunol</i>. 2011;127(3):840]. <i>J Allergy Clin Immunol</i>. 2011;127(1 suppl):S1-S55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/house-dust-mite-sublingual-tablet-drug-information/abstract-text/21122901/pubmed\" target=\"_blank\" id=\"21122901\">21122901</a>]</span><span class=\"doi\">10.1016/j.jaci.2010.09.034</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larenas-Linnemann DE, Hauswirth DW, Calabria CW, Sher LD, Rank MA. American Academy of Allergy, Asthma &amp; Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions. <i>Allergy Asthma Proc</i>. 2016;37(5):112-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/house-dust-mite-sublingual-tablet-drug-information/abstract-text/27657518/pubmed\" target=\"_blank\" id=\"27657518\">27657518</a>]</span><span class=\"doi\">10.2500/aap.2016.37.3981.</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leith E, Bowen T, Butchey J, et al. Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI). <i>Allergy Asthma Clin Immunol</i>. 2006;2(2):47-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/house-dust-mite-sublingual-tablet-drug-information/abstract-text/20525157/pubmed\" target=\"_blank\" id=\"20525157\">20525157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Odactra (house dust mite allergen extract) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oykhman P, Kim HL, Ellis AK. Allergen immunotherapy in pregnancy. <i>Allergy Asthma Clin Immunol</i>. 2015;11:31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/house-dust-mite-sublingual-tablet-drug-information/abstract-text/26561490/pubmed\" target=\"_blank\" id=\"26561490\">26561490</a>]</span><span class=\"doi\">10.1186/s13223-015-0096-7.</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaikh WA, Shaikh SW. A prospective study on the safety of sublingual immunotherapy in pregnancy. <i>Allergy</i>. 2012;67(6):741-743.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/house-dust-mite-sublingual-tablet-drug-information/abstract-text/22486626/pubmed\" target=\"_blank\" id=\"22486626\">22486626</a>]</span><span class=\"doi\">10.1111/j.1398-9995.2012.02815.x.</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 112242 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F49661634\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50280301\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50280302\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F49661636\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50010713\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50010714\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50010715\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F50870967\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F50870966\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50280303\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49661633\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50010716\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F49661638\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F49710911\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F49661639\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50010709\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F49711511\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F49711508\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50010707\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50010708\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50010718\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50010712\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F51083809\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49710651\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/112242|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=house-dust-mite-sublingual-tablet-patient-drug-information\" class=\"drug drug_patient\">House dust mite sublingual tablet: Patient drug information</a></li></ul></div></div>","javascript":null}